Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient

摘要

Linezolid has good activity against staphylococci and enterococci, inhibiting the majority of strains at concentrations between 1 and 4 μg/ml (1, 2). The susceptibility breakpoint for Enterococcus spp. is fixed by the European Committee on Antimicrobial Susceptibility Testing at ≤4 μg/ml (http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables) and by the Clinical and Laboratory Standards Institute at ≤2 μg/ml (3).